SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma reports 50% jump in Q1 consolidated net profit

05 Aug 2025 Evaluate

Gland Pharma has reported result for first quarter ended June 30, 2025 (Q1FY26).

The company has reported 20.79% rise in its net profit at Rs 269.26 crore for the quarter ended June 30, 2025 as compared to Rs 222.92 crore for the same quarter in the previous year. The total income of the company increased by 3.12% at Rs 1093.58 crore for Q1FY26 as compared to Rs 1060.51 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 49.89% jump in its net profit at Rs 215.48 crore for Q1FY26 as compared to Rs 143.76 crore for the same quarter in the previous year. The total income of the company increased by 7.57% at Rs 1563.15 crore for Q1FY26 as compared to Rs 1453.14 crore for the corresponding quarter previous year.

Gland Pharma Share Price

1759.95 3.95 (0.22%)
16-Apr-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1707.65
Dr. Reddys Lab 1219.05
Cipla 1234.90
Zydus Lifesciences 937.75
Lupin 2341.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×